Fairvalue-Calculator Fairvalue-Calculator
EN DE

Lepu Medical Technology (Beijing) Co (300003) Fair Value & Analysis

Healthcare · CN · Market cap 21.8B CNY

Price¥11.81
Fair Value¥11.48
Upside-2.8%
Quality86/100
Evidence: Medium Range ¥8.61 – ¥14.35

Analysis

Lepu Medical Technology (Beijing) Co (300003) currently trades at ¥11.81, while our model-based Fair Value estimate is ¥11.48 — implying the stock looks roughly 2.8% overvalued today. We read business quality at 86/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Lepu Medical Technology (Beijing) Co., Ltd., together with its subsidiaries, engages in the research, development, and manufacturing of cardiac interventional medical devices in China and internationally. The company operates through three segments: Medical Devices; Pharmaceuticals; and Medical Services and Health Management. It offers medical devices, including cardiovascular devices, in vitro diagnostics, surgical instruments, peripheral blood vessels, blood purification, ultrasound imaging, and orthopedic products; pharmaceutical products for cardiovascular, digestive, central nervous, and respiratory systems, as well as antimicrobial, nutrition, traditional Chinese medicine, lowering blood sugar, and health food; and medical services and health management, such as medical services, AI, home appliances, and medical aesthetics and daily chemical products. The company is also involved in investment activities; trading; technological development; and pension services. It exports its…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -20% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.